Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2025 | Preliminary insights from a 12-week app-based intervention in patients with cognitive decline

Felix Bicu, MD, memodio, Potsdam, Germany, reports preliminary findings from a randomized controlled trial investigating the efficacy of a multidomain digital health intervention for patients with cognitive decline. Dr Bicu reports significant improvements in cognitive outcomes in patients who used the app for 12 weeks. This interview took place at the 11th Congress of the European Academy of Neurology (EAN 2025) in Helsinki, Finland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Before the study actually started, there needs to be the development of the app. And we spent quite a lot of time in UX, so usability development. It’s adapted to the needs of the older patient. All the buttons are larger buttons, or still even if it’s a touch screen, because scrolling is not so easy sometimes for people with cognitive decline and other key features. And the study consists of two groups, so it’s a randomized controlled study with two arms...

Before the study actually started, there needs to be the development of the app. And we spent quite a lot of time in UX, so usability development. It’s adapted to the needs of the older patient. All the buttons are larger buttons, or still even if it’s a touch screen, because scrolling is not so easy sometimes for people with cognitive decline and other key features. And the study consists of two groups, so it’s a randomized controlled study with two arms. One arm gets care as usual. The care as usual is defined by the leading doctor or by the treating doctor in a university clinic setting or clinic setting. And one other group gets the care as usual, additionally to the app for 12 weeks. And after 12 weeks, so you start with measuring four outcomes, MOCA for cognitive outcomes, Amsterdam EADL in short form for the activities of daily living, PAC50 for physical activity, and we also measured the quality of life with a DEMQOL. And we saw in 12 weeks a difference between the both groups was about, now since the study is fully finalized at the beginning of this year, we saw in the cognitive improvement or a difference between the intervention group, so for the benefit of the intervention group for about 9%. And for activity, a 21% increase of activity compared to the group with the intervention, with the app. And for quality of life and for activities of daily living, a difference of 4% beneficial to the app treatment. So yeah, the app confirms the study results from other big studies for non-pharmacological treatments.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Disclosures

memodio GmbH founder.